← All trials
NCT05894577
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 27, 2023
- Primary completion
- Jul 31, 2023
- Completion date
- Jan 2, 2024
- First posted
- Jun 8, 2023
- Last posted
- Nov 7, 2023
- Enrollment
- 1403
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Duke UniversityLead sponsor
- Duke UniversityOverall official - principal investigator
- Duke UniversityOverall official - principal investigator
- Duke UniversitySponsor investigator
- Vanderbilt UniversityCollaborator
- National Center for Advancing Translational Science (NCATS)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.